###begin article-title 0
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
Association of Common Polymorphisms in GLUT9 Gene with Gout but Not with Coronary Artery Disease in a Large Case-Control Study
###end article-title 0
###begin p 1
Conceived and designed the experiments: CH KS WR SW. Performed the experiments: KS KN SW BK. Analyzed the data: CH KS WR KN SW KS AB MF SW BK. Contributed reagents/materials/analysis tools: CH KS WR. Wrote the paper: CH KS WR KN SW KS AB MF SW BK JE HS.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 502 507 502 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
Serum uric acid (UA) levels have recently been shown to be genetically influenced by common polymorphisms in the GLUT9 gene in two genome-wide association analyses of Italian and British populations. Elevated serum UA levels are often found in conjunction with the metabolic syndrome. Hyperuricemia is the major risk factor for gout and has been associated with increased cardiovascular morbidity and mortality. The aim of the present study was to further elucidate the association of polymorphisms in GLUT9 with gout and coronary artery disease (CAD) or myocardial infarction (MI). To test our hypotheses, we performed two large case-control association analyses of individuals from the German MI Family Study.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 187 192 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 461 462 461 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 473 475 473 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 703 708 703 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 895 900 895 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
First, 665 patients with gout and 665 healthy controls, which were carefully matched for age and gender, were genotyped for four single nucleotide polymorphisms (SNPs) within or near the GLUT9 gene. All four SNPs demonstrated highly significant association with gout. SNP rs6855911, located within intron 7 of GLUT9, showed the strongest signal with a protective effect of the minor allele with an allelic odds ratio of 0.62 (95% confidence interval 0.52-0.75; p  =  3.2*10-7). Importantly, this finding was not influenced by adjustment for components of the metabolic syndrome or intake of diuretics. Secondly, 1,473 cases with severe CAD or MI and 1,241 healthy controls were tested for the same four GLUT9 SNPs. The analyses revealed, however, no significant association with CAD or with MI. Additional screening of genome-wide association data sets showed no signal for CAD or MI within the GLUT9 gene region.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
Thus, our results provide compelling evidence that common genetic variations within the GLUT9 gene strongly influence the risk for gout but are unlikely to have a major effect on CAD or MI in a German population.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 82 85 82 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Luk1">[1]</xref>
###xml 338 341 338 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Campion1">[2]</xref>
###xml 531 534 531 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Choi1">[3]</xref>
###xml 646 649 646 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Luk1">[1]</xref>
###xml 976 979 976 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Fam1">[4]</xref>
###xml 981 984 981 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Pascual1">[5]</xref>
###xml 56 59 <span type="species:ncbi:9606">men</span>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
Gout is the most frequent inflammatory joint disease in men above 40 years of age [1]. It is characterized by chronic hyperuricemia, usually defined as serum uric acid (UA) levels >7 mg/dL, and recurrent attacks of acute arthritis in one-third of the patients triggered by the release of monosodium urate crystals into the synovial space [2]. In the majority of patients with primary gout, hyperuricemia results from inefficient renal excretion, while in about 10% of cases, hyperuricemia is due to endogenous overproduction of UA [3]. Gout is an increasingly common medical problem with an overall prevalence of at least 1% in Western societies [1]. The reasons for the rise in incidence and prevalence of gout are closely linked to its known association with dietary habits, such as overindulgence in food and alcohol, and with it the intricately connected metabolic syndrome and its components insulin resistance, abdominal obesity, dyslipidemia, and arterial hypertension [4], [5].
###end p 9
###begin p 10
###xml 301 304 301 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Culleton1">[6]</xref>
###xml 305 308 305 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Niskanen1">[8]</xref>
###xml 863 866 863 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Wellcome1">[9]</xref>
###xml 867 871 867 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Zeggini1">[17]</xref>
###xml 1003 1008 1003 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 1029 1035 1029 1035 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLC2A9</italic>
###xml 1080 1084 1080 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Li1">[18]</xref>
###xml 1086 1090 1086 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Wallace1">[19]</xref>
###xml 1182 1186 1182 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Phay1">[20]</xref>
The role of hyperuricemia as an independent risk factor for coronary artery disease (CAD) and myocardial infarction (MI) has been discussed controversially for many years since several but not all epidemiologic studies found an independent association of elevated serum UA with cardiovascular disease [6]-[8]. Experimental data to support the hypothesis of a causal relationship between hyperuricemia and CAD are scarce. However, recent genetic data might add further insights into the pathophysiology of hyperuricemia and its possible link to cardiovascular disease. The availability of large-scale genome-wide association (GWA) studies using 500,000 or more single nucleotide polymorphism (SNP) markers equally distributed across the genome, now facilitates identification of susceptibility genes in polygenic and complex phenotypes, e.g. type 2 diabetes or MI [9]-[17]. For hyperuricemia, two very recent GWA studies in an isolated Sardinian population and in a British cohort identified SNPs in the GLUT9 gene, also known as SLC2A9, to significantly influence serum UA levels [18], [19]. GLUT9 is a transmembrane glucose transporter that is highly expressed in liver and kidney [20].
###end p 10
###begin p 11
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 457 462 457 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
The aims of this study were thus to further assess the association of GLUT9 polymorphisms in the phenotypic expression of gout and their possible role in susceptibility to CAD, assuming an independent influence of hyperuricemia on the development of cardiovascular disease. For this purpose, we examined two large, separate case-control samples of individuals from the German MI Family Study and included also the results from two CAD/MI GWA studies at the GLUT9 gene region to analyse potential additive effects.
###end p 11
###begin title 12
Materials and Methods
###end title 12
###begin title 13
Populations
###end title 13
###begin p 14
###xml 80 81 80 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Broeckel1">[21]</xref>
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Sedlacek1">[22]</xref>
All individuals of this study participated in the German MI Family Study (total n  =  7,575). Recruitment process, selection criteria and study details have been reported previously [21], [22]. In brief, we identified families from all parts of Germany with accumulation of premature MI or severe CAD. Control individuals were unaffected spouses of MI family members and had no genetic relationship to cases.
###end p 14
###begin p 15
###xml 89 101 <span type="species:ncbi:9606">participants</span>
The Ethics committee of the University of Regensburg approved the study protocol and all participants gave their written informed consent at the time of inclusion and again at the time of follow-up investigations. The study was in accordance with the principles of the current version of the Declaration of Helsinki.
###end p 15
###begin title 16
Phenotyping
###end title 16
###begin p 17
The baseline home visit was performed by a physician and included a standardized questionnaire, physical examination, and biochemical analyses. A standardized follow-up interview regarding new medical events was carried out by specially trained telephone interviewers after two and five years. Cardiovascular events at study entry and follow-up were validated by reviewing medical records.
###end p 17
###begin p 18
###xml 585 589 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Hense1">[23]</xref>
###xml 533 545 <span type="species:ncbi:9606">participants</span>
The phenotype gout was carefully established using two levels of evidence: 1. medical history readings at time of inclusion, two-year and five-year follow-up interview; and 2. self-reported history of gout. The diagnosis of MI was established according to the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) diagnostic criteria (). Severe CAD was defined as treatment with percutaneous coronary intervention or coronary artery bypass graft. Resting blood pressure was taken according to MONICA guidelines after participants had been resting in a sitting position [23]. Hypertension was defined as blood pressure >/=140/90 mm Hg or ongoing antihypertensive therapy. Body weight was determined with subjects wearing light clothing. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. Sampling of serum was carried out from non-fasting individuals. Serum levels of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were measured by standard enzymatic methods. Hypercholesterolemia was defined as LDL-C >/=160 mg/dL or intake of lipid lowering medication. History of diabetes mellitus or intake of antidiabetic medication was used to define type 2 diabetes. Smoking was defined as current or former smoking habit.
###end p 18
###begin title 19
Case-control samples
###end title 19
###begin p 20
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 34 35 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 51 52 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
A total of n  =  665 individuals (n  =  479 males, n  =  186 females) with the diagnosis of gout were selected from the German MI Family Study. All gout cases fulfilled the above mentioned criteria for "gout". Controls were unrelated individuals from our German MI Family Study who did neither have any indication for gout nor were they medicated with uricostatics or uricosuric agents at any time during follow-up.
###end p 20
###begin p 21
###xml 45 46 45 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 143 150 143 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t001">Table 1</xref>
We carefully matched the gout-free controls (n  =  665) according to age and gender to the gout cases. Further phenotypic details are shown in Table 1.
###end p 21
###begin title 22
Characteristics of gout case and control study sample.
###end title 22
###begin p 23
Values denote means +/- standard deviations unless indicated otherwise. n. s., not significant; CAD, coronary artery disease; MI, myocardial infarction; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index.
###end p 23
###begin p 24
Matching parameter.
###end p 24
###begin p 25
Defined as LDL-C >/=160 mg/dL or intake of lipid lowering medication.
###end p 25
###begin p 26
Defined as blood pressure >/=140/90 mm Hg or ongoing antihypertensive therapy.
###end p 26
###begin p 27
Defined as history of diabetes mellitus or intake of antidiabetic medication.
###end p 27
###begin p 28
Former or current smoking habit.
###end p 28
###begin p 29
###xml 285 292 285 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t002">Table 2</xref>
Futhermore, a large case-control sample was established from the German MI Family Study including 1,473 CAD/MI cases (856 male, 617 female) and 1,241 unrelated CAD/MI-free control individuals (336 male, 905 female). Cardiovascular risk factors and phenotypic details are summarized in Table 2.
###end p 29
###begin title 30
Characteristics of CAD case and control study sample.
###end title 30
###begin p 31
Values denote means +/- standard deviations unless indicated otherwise. CAD, coronary artery disease; MI, myocardial infarction; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index.
###end p 31
###begin p 32
Defined as LDL-C >/=160 mg/dL or intake of lipid lowering medication.
###end p 32
###begin p 33
Defined as blood pressure >/=140/90 mm Hg or ongoing antihypertensive therapy.
###end p 33
###begin p 34
Defined as history of diabetes mellitus or intake of antidiabetic medication.
###end p 34
###begin p 35
Former or current smoking habit.
###end p 35
###begin title 36
SNP selection and genetic analyses
###end title 36
###begin p 37
###xml 5 10 5 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 223 227 223 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Li1">[18]</xref>
###xml 229 233 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Wallace1">[19]</xref>
Four GLUT9 SNPs were selected from a public reference database (dbSNP, ) based on the following criteria: (1) evidence for significant association with serum UA levels from two recent publications (rs6855911 and rs7442295) [18], [19], (2) minor allele frequency of >0.10 in a Caucasian population, (3) evidence of validation status, and (4) compatibility with our genotyping platform. To allow determination of the extend of LD beyond the boundaries of the gene, one SNP in the 5' intergenic region was included.
###end p 37
###begin p 38
###xml 1263 1268 1253 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 916 922 <span type="species:ncbi:9606">person</span>
###xml 1070 1075 <span type="species:ncbi:9606">Human</span>
###xml 1313 1318 <span type="species:ncbi:9606">human</span>
Genomic DNA was isolated from whole blood samples using the PureGene DNA Blood Kit (Gentra, Minneapolis, MN, USA). DNA samples were genotyped using 5' exonuclease TaqMan(R) technology (Applied Biosystems, Foster City, CA, USA). For each genotyping experiment 10 ng DNA was used in a total volume of 5 microl containing 1x TaqMan(R) Genotyping Master Mix (Applied Biosystems). PCR reaction and post-PCR endpoint plate read was carried out according to the manufacturer's instructions using the Applied Biosystems 7900HT Real-Time PCR System. Sequence Detection System software version 2.3 (Applied Biosystems) was used to assign genotypes applying the allelic discrimination test. Case and control DNA was genotyped together on the same plates with duplicates of samples (15%) to assess intraplate and interplate genotype quality. No genotyping discrepancies were detected. Assignment of genotypes was performed by a person without knowledge of the proband's affection status. Additionally, comparison between genotype calls from TaqMan assays and Affymetrix GeneChip(R) Human Mapping 500K Array Set were carried out in 288 DNA samples on all four SNPs (rs6855911, rs7442295, rs6449213, and rs12510549). Again, no discrepancies were found. SNPs were mapped to the GLUT9 gene according to NM_001001290 (position on human genome build 18: chromosome 4; 9,436,948-9,650,970).
###end p 38
###begin p 39
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 152 156 152 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Samani1">[12]</xref>
###xml 272 277 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 398 404 396 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001948-g001">Fig. 1</xref>
###xml 220 225 <span type="species:ncbi:9606">Human</span>
###xml 360 365 <span type="species:ncbi:9606">human</span>
Genome-wide data from two recently published screens for polymorphisms associated with CAD or MI were employed to survey the complete GLUT9 gene region [12]. All successfully genotyped SNPs on the Affymetrix GeneChip(R) Human Mapping 500K Array Set on chromosome 4 in the GLUT9 region with 500 kb on either side of the gene (position 8,936,948 and 10,150,970; human genome build 18) were included (Fig. 1).
###end p 39
###begin title 40
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 122 127 <span type="species:ncbi:9606">human</span>
Schematic representation of a approximately1,214 kb region on human chromosome 4p16.1 (position 8,936,948 and 10,150,970; human genome build 18) used for association analyses.
###end title 40
###begin p 41
###xml 541 546 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 628 629 628 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 629 630 629 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 771 772 771 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 772 773 772 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 793 794 793 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 794 795 794 795 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 855 856 855 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 856 857 856 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Position numbers are given on top. (A) Relative positions of SNPs analyzed in this study. GWA SNPs from WTCCC and Cardiogenics CAD/MI case-control study are shown above the four SNPs genotyped in this work (gt SNPs). From left to right: rs6855911, rs7442295, rs6449213, and rs12510549. (B) Graphic illustration of genes in this genomic region. Relative positions of RefSeq genes with gene names are presented. Exons are depicted as vertical blocks and orientation of genes is indicated by arrows on the horizonal lines representing introns. GLUT9 gene is highlighted with bold letters. (C) Delineation of LD structure. Pairwise r2-values between markers from HapMap phase II release 22 for the CEPH (CEU) sample were calculated and presented. Red denotes perfect LD with r2 = 1 and decreasing r2-values are shown in brighter color with white representing r2 = 0.
###end p 41
###begin p 42
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Frazer1">[24]</xref>
Data of the HapMap phase II release 22 data were used to assess linkage disequilibrium (LD) patterns of the GLUT9 gene region [24].
###end p 42
###begin title 43
Statistical analyses
###end title 43
###begin p 44
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 189 190 187 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 615 620 613 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 710 718 708 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t001">Tables 1</xref>
###xml 720 721 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t002">2</xref>
###xml 819 820 817 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 923 924 921 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
To determine whether the genotypes of cases and controls of all GLUT9 SNPs deviated from Hardy-Weinberg equilibrium, actual and predicted genotype counts of both groups were compared by chi2-test. Differences in allele frequencies between dichotomous traits were calculated employing the same method. Genotypes were coded for both dominant and recessive effects (genotype 22+12 versus 11 and genotype 22 versus 11+12, respectively, with the minor allele coded as 2). The additive genetic model was calculated using Armitage's trend test. Multiple logistic regression analysis was used to examine the association of GLUT9 SNPs with either phenotype (gout or CAD/MI) allowing adjustment for relevant covariates (Tables 1, 2). Differences in continuous variables between groups were calculated using a two-tailed unpaired t-test. Prevalence odds ratios (OR) with their 95% confidence intervals (CI) were reported. A two-sided p-value </=0.05 was considered statistically significant.
###end p 44
###begin p 45
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Purcell1">[25]</xref>
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Purcell1">[25]</xref>
###xml 195 199 195 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Barrett1">[26]</xref>
###xml 266 270 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Faul1">[27]</xref>
Association analyses were performed using JMP IN 7.0.1 (SAS Institute Inc, Cary, NC, USA) and PLINK v1.00 [25]. For haplotype analysis and permutation testing PLINK v1.00 [25] and HaploView v4.0 [26] were employed. Power analysis was carried out using G*Power 3.0.8 [27].
###end p 45
###begin title 46
Results
###end title 46
###begin title 47
Population characteristics
###end title 47
###begin p 48
###xml 46 47 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 113 114 113 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 738 745 738 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t001">Table 1</xref>
In our first case-control cohort, gout cases (n  =  665) were matched for age and gender to control individuals (n  =  665). Prevalence of cardiovascular risk factors and cardiovascular disease was high in both, gout cases and gout-free controls. Gout cases were more often treated with diuretics as compared to controls. In addition, in gout cases, the prevalence of type 2 diabetes and increased BMI was higher, whereas in gout-free controls HDL-C levels were elevated. However, we found no significant difference in number of reported MI or CAD events between gout cases (67.5% CAD/MI) and gout-free controls (65.9% CAD/MI). Prevalence of hypercholesterolemia, hypertension and smoking were equally distributed between the two groups (Table 1).
###end p 48
###begin p 49
###xml 250 251 250 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 288 289 288 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 302 309 302 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t002">Table 2</xref>
###xml 432 439 432 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t002">Table 2</xref>
In our second, large case-control sample for CAD/MI the incidence of established cardiovascular risk factors, such as male gender, type 2 diabetes, hypercholesterolemia, hypertension and smoking, as well as increased BMI, was higher in CAD/MI cases (n  =  1,473) as compared to controls (n  =  1,241) (Table 2). Interestingly, we also found more individuals suffering from gout in our CAD/MI cases compared to CAD/MI-free controls (Table 2).
###end p 49
###begin title 50
Genetic analyses
###end title 50
###begin p 51
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 208 215 208 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t003">Table 3</xref>
###xml 390 394 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Li1">[18]</xref>
###xml 436 437 436 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 435 437 435 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r<sup>2</sup></italic>
###xml 549 550 549 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 548 550 548 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r<sup>2</sup></italic>
###xml 559 566 557 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t003">Table 3</xref>
The cohorts were genotyped for markers rs6855911, rs7442295, and rs6449213 located in GLUT9 intron 7, 6, and 4, respectively. Additionally, rs12510549, 235 kb upstream of GLUT9, was included in the analysis (Table 3). All SNPs fulfilled our criteria of at least 98.5% call rate in all sub-samples. Marker rs6855911 and rs7442295 were reported to be strongly associated with serum UA levels [18]. Pairwise LD analysis showed decreasing r2-values from rs6855911 to rs12510549 although LD between the four markers remained on an overall high level of r2>/=0.45 (Table 3).
###end p 51
###begin title 52
SNP marker used in analysis.
###end title 52
###begin p 53
calculated in gout case-control sample with 1,304 individuals without any missing genotype.
###end p 53
###begin p 54
on chromosome 4 (hg18).
###end p 54
###begin title 55
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
Association analysis of GLUT9 SNPs in the gout case-control sample
###end title 55
###begin p 56
###xml 87 94 87 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t004">Table 4</xref>
###xml 192 193 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 204 205 204 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 216 217 216 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 232 233 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 374 375 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 386 387 386 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 398 399 398 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 414 415 414 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Genotype distributions and allele frequencies in gout case-control cohort are shown in Table 4. There was no significant deviation from Hardy-Weinberg equilibrium (HWE) in gout-free controls (p  =  0.43, p  =  0.45, p  =  0.34, and p  =  0.21 for rs6855911, rs7442295, rs6449213, and rs12510549, respectively). In contrast, there was a deviation from the HWE in gout cases (p  =  0.04, p  =  0.01, p  =  0.01, and p  =  0.02 for rs6855911, rs7442295, rs6449213, and rs12510549, respectively).
###end p 56
###begin title 57
Association analysis results in gout case-control sample.
###end title 57
###begin p 58
###xml 89 96 89 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t003">Table 3</xref>
MAF: minor allele frequency; numbers of genotypes (11, 12, 22) according to alleles from Table 3.
###end p 58
###begin p 59
###xml 64 71 64 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t004">Table 4</xref>
###xml 108 109 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 120 122 120 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 279 286 279 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t004">Table 4</xref>
###xml 449 450 449 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 461 463 461 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
Strong association with gout was observed for all four markers (Table 4). The highest significance level of p  =  2.9*10-7 was detected for genotype distribution of marker rs6855911. We found a protective effect of the minor allele with an allelic OR of 0.62 (95% CI 0.52-0.75) (Table 4). Multivariate logistic regression analysis adjusting for BMI, type 2 diabetes, and medication with diuretics even increased the significance of the association (p  =  4.6*10-8). Hence, effect of marker rs6855911 on susceptibility to gout is independent of common cardiovascular risk factors and several components of the metabolic syndrome.
###end p 59
###begin p 60
###xml 165 172 165 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t005">Table 5</xref>
In addition to allele frequency and genotype distribution, we analyzed additive, dominant and recessive genetic models with no substantial increase in significance (Table 5).
###end p 60
###begin title 61
Results from different genetic models in gout case-control sample.
###end title 61
###begin p 62
###xml 130 131 130 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 553 554 553 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 570 572 570 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 725 726 725 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 737 739 737 739 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 909 910 909 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 921 923 921 923 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 937 938 937 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 949 951 949 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 302 310 <span type="species:ncbi:261946|species:ncbi:501646|species:ncbi:34344|species:ncbi:526811|species:ncbi:338539|species:ncbi:369518">e. major</span>
###xml 402 410 <span type="species:ncbi:9606">patients</span>
According to the high LD between the SNPs, four-marker haplotypes were constructed spanning a 340-kb genomic region. Nine of the 42 possible haplotypes could be observed with only two (AATT and GGCC) having frequencies >0.05 in cases and controls of the gout sample. The most common haplotype AATT (i. e. major allele from each marker) was less frequently present in healthy individuals as compared to patients with gout (frequency in gout-free controls  =  0.691; frequency in gout cases  =  0.780), i. e. representing a risk haplotype, resulting in a p-value of 2.2*10-7. The second common haplotype (GGCC) codes for a protective haplotype with frequency in controls of 0.183 and frequency in cases of 0.126, respectively (p  =  4.5*10-5). After adjustment for BMI, type 2 diabetes, and medication with diuretics in a multivariate logistic regression analysis, the association results remained significant (p  =  1.3*10-7 for AATT and p  =  2.9*10-5 for GGCC).
###end p 62
###begin p 63
###xml 122 123 120 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 159 160 155 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Both, single marker and haplotype association analysis remained significant after 100,000 permutations. No permutation chi2-value exceeded highest observed chi2-value.
###end p 63
###begin p 64
###xml 150 157 150 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t006">Table 6</xref>
###xml 176 183 176 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t007">Table 7</xref>
Separate analyses in females and males revealed similar odds ratios in allele frequency comparisons but slightly higher significance levels in males (Table 6) than in females (Table 7).
###end p 64
###begin title 65
Association analysis results in male gout case-control sample.
###end title 65
###begin p 66
###xml 89 96 89 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t003">Table 3</xref>
MAF: minor allele frequency; numbers of genotypes (11, 12, 22) according to alleles from Table 3.
###end p 66
###begin title 67
Association analysis results in female gout case-control sample.
###end title 67
###begin p 68
###xml 89 96 89 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t003">Table 3</xref>
MAF: minor allele frequency; numbers of genotypes (11, 12, 22) according to alleles from Table 3.
###end p 68
###begin p 69
###xml 63 64 61 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
n. a.: not applicable due to low counts of minor allele for chi2.
###end p 69
###begin title 70
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
Association analysis of GLUT9 SNPs in the CAD/MI case-control sample
###end title 70
###begin p 71
###xml 137 138 137 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 159 160 159 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 190 197 190 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t002">Table 2</xref>
###xml 438 439 438 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Our power calculation indicated that at a significance level of 0.05 and with a two-sided alternative hypothesis, our CAD/MI sample with n  =  1,473 cases and n  =  1,241 CAD-free controls (Table 2) had more than 97% power to detect a significant association with an assumed OR of 1.4 between the tested polymorphisms and the phenotype. HWE criteria for the four genotyped markers were fulfilled in CAD/MI cases and CAD/MI-free controls (p>0.4).
###end p 71
###begin p 72
###xml 67 74 67 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t008">Table 8</xref>
###xml 169 170 169 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 379 380 379 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 446 447 446 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 469 470 469 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 492 493 492 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 516 517 516 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 987 988 987 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
No association with CAD was observed for any of the analyzed SNPs (Table 8). To evaluate the impact of a more stringent phenotype definition, we included only MI cases (n  =  1,114) as a sub-sample of CAD patients in a separate analysis. Again, no significant difference in allele or genotype frequencies of the four genotyped markers between MI cases and disease-free controls (n  =  1,241) was observed (e. g. genotype distribution; rs6855911, p  =  0.42; rs7442295, p  =  0.27; rs6449213, p  =  0.70; rs12510549, p  =  0.81). Multivariate logistic regression analysis adjusting for cardiovascular risk factors (age at first manifestation, male gender, type 2 diabetes, hypercholesterolemia, hypertension, smoking, and BMI) both on single SNPs and haplotypes in CAD/MI case-control sample did not reveal positive association results (data not shown). Separate analysis for male and female individuals did not point to gender-specific effects of the four SNPs and CAD/MI in trend test (p>0.18).
###end p 72
###begin title 73
Association analysis results in CAD case-control sample.
###end title 73
###begin p 74
###xml 89 96 89 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t003">Table 3</xref>
MAF: minor allele frequency; numbers of genotypes (11, 12, 22) according to alleles from Table 3.
###end p 74
###begin p 75
###xml 606 607 606 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 641 642 641 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
To gain maximum power for detection of even small effects, we included all appropriate individuals from our German MI Family Study in the CAD/MI case-control sample. This included an overlap of 220 individuals from gout case sample in CAD/MI case sample, 337 individuals from gout control sample in CAD/MI case sample, 108 individuals from gout case sample in CAD/MI control sample, and 217 individuals from gout control sample in CAD/MI control sample, respectively. After an initial round of association testing with CAD/MI, we excluded all overlapping individuals from the analysis. Again, in remaining n  =  916 CAD/MI cases compared to n  =  916 controls neither SNPs nor haplotypes achieved statistical significance, even after adjustment for age of first manifestation of CAD/MI, male gender, type 2 diabetes, hypercholesterolemia, hypertension, smoking, and BMI (data not shown).
###end p 75
###begin p 76
###xml 76 81 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 202 206 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Samani1">[12]</xref>
###xml 283 284 283 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 403 408 403 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 480 485 480 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 506 512 506 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001948-g001">Fig. 1</xref>
###xml 556 557 556 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
To assess the possibility that other markers located within or close to the GLUT9 gene could exert influence on susceptibility to CAD or MI, we analyzed the data from two recently conducted GWA studies [12]. Both, from British (WTCCC) and German (Cardiogenics) case-control samples, p-values were obtained for association with CAD/MI (WTCCC) and MI (Cardiogenics). A total of 292 SNP markers located in GLUT9 gene region (214 kb) and a more extended region of 1,000 kb around the GLUT9 gene were analyzed (Fig. 1). None of the SNPs showed association at a p<0.05 with CAD/MI in the WTCCC and Cardiogenics cohorts.
###end p 76
###begin title 77
Discussion
###end title 77
###begin p 78
###xml 105 110 105 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 206 211 206 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 364 368 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Li1">[18]</xref>
###xml 370 374 370 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Wallace1">[19]</xref>
This study investigated the relationship between four common sequence variants and haplotypes within the GLUT9 gene region with gout and CAD/MI in two German case-control samples. We were led to pursue the GLUT9 gene because of very recent findings that sequence variants in this gene significantly influence the serum UA levels in Italian and British populations [18], [19].
###end p 78
###begin p 79
###xml 43 47 43 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Annemans1">[28]</xref>
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Choi2">[29]</xref>
###xml 255 259 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Shoji1">[30]</xref>
###xml 358 362 358 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Choi3">[31]</xref>
###xml 474 478 474 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Choi3">[31]</xref>
###xml 401 404 <span type="species:ncbi:9606">men</span>
###xml 457 460 <span type="species:ncbi:9606">men</span>
The prevalence for gout in Germany is 1.4% [28], whereas lifestyle plays an important role on its epidemiology [29]. Hyperuricemia, i. e. high serum UA levels, are associated with the occurrence of gout with some pathophysiologic details still unresolved [30]. The role of gout as a risk factor for CAD and MI was recently demonstrated in epidemiologic data [31]. This prospective study revealed that men with gout had a 59% higher risk of nonfatal MI than men without gout [31].
###end p 79
###begin p 80
###xml 376 380 376 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Conen1">[32]</xref>
###xml 382 386 382 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Dehghan1">[33]</xref>
However, it is still controversial whether hyperuricemia independently predicts cardiovascular events. It is furthermore unclear whether it relates to cardiovascular disease by a complex interaction with several classical risk factors, such as arterial hypertension, obesity, hypercholesterolemia and insuline resistance, all of which are components of the metabolic syndrome [32], [33].
###end p 80
###begin p 81
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Yusuf1">[34]</xref>
###xml 336 340 336 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Mayer1">[35]</xref>
###xml 478 482 478 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Helgadottir1">[10]</xref>
###xml 483 487 483 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Samani1">[12]</xref>
The overall cardiovascular risk is caused by factors like smoking, hypercholesterolemia, hypertension, type 2 diabetes, abdominal obesity, psychosocial factors, physical activity, and nutrition [34]. Additionally, genetic variations modulate not only some of these classical cardiovascular risk factors but act also in a complex manner [35]. Alleles directly influencing susceptibility to CAD or MI in a still unknown fashion were consistently found in three recent GWA studies [10]-[12].
###end p 81
###begin p 82
###xml 97 102 97 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 207 212 207 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 662 667 662 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 781 785 781 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Li1">[18]</xref>
###xml 1110 1114 1110 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Underwood1">[36]</xref>
###xml 1480 1485 1480 1485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
To our knowledge, the present study offers the first case-control association analysis of common GLUT9 variants with the qualitative phenotypes gout and CAD/MI. We report strong association between all four GLUT9 SNPs and gout consistently showing a protective effect of the minor alleles with an odds ratio of 0.62. The effect was not influenced by multivariate adjustment for cardiovascular risk factors or metabolic traits and, importantly, intake of diuretic medication pointing to a largely independent genetic effect. Our results are consistent with the findings of Li et al., who demonstrated a significant negative additive effect of about 0.40 mg/dL of GLUT9 polymorphisms rs6855911 and rs7442295 on serum UA levels resulting from a protective effect of the minor alleles [18]. Therefore, these SNP markers could be helpful for stratification of risk for gout in the general population. Although gout is generally regarded as a disease that is easy to diagnose and has an effective treatment, in less typical cases - particularly in the elderly - the strictly clinical diagnosis becomes less accurate [36]. Misdiagnosing of gout or gouty arthritis as osteoarthritis, rheumatoid arthritis, septic arthritis, or other rheumatic conditions may lead to inappropriate treatment and result in unnecessary morbidity. To support the diagnosis of these atypical presentations genetic testing could be beneficial, help to prevent clinical mismanagement and avoid costs. Maybe, the GLUT9 gene may even provide a new therapeutic target for hyperuricemia and gout in the future.
###end p 82
###begin p 83
###xml 332 336 332 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Xu1">[37]</xref>
###xml 560 561 560 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 585 586 585 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
For all genotyped markers, we found moderate deviation from HWE in gout cases. Generally, deviations from HWE can point to either a sampling bias or population stratification. Whereas HWE deviations in a control sample suggest the possibility of genotyping errors, HWE deviations in cases can also be the result of true association [37]. We deliberately focused on common sequence variants with MAF between 15 and 20%, as it is more likely that these frequent variants play a role in the general population. Thus, with the MAF being this high, our sample with n  =  665 gout cases and n  =  665 controls had enough power (>80% with an assumed change of 40% in OR) to detect a true effect.
###end p 83
###begin p 84
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 205 206 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 344 348 344 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Cupples1">[38]</xref>
###xml 376 377 376 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 653 658 653 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 799 800 799 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 811 813 811 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 223 235 <span type="species:ncbi:9606">participants</span>
Additional evidence for a reliable positive association between GLUT9 SNPs and gout came from analysis of the Framingham SNP Health Association Resource (SHARe) posted on the NCBI dbGaP website at . Here, n  =  1,345 adult participants of the largest 310 pedigrees in the Framingham Heart Study were genotyped with the Affymetrix 100K GeneChip [38]. Age, sex and BMI adjusted p-values for the phenotype gout (defined as history of gout at any examination cycle) were available (accession: pha001406.1). However, the four SNPs analyzed in our study (rs6855911, rs7442295, rs6449213, and rs12510549) were not included on the Affymetrix 100K GeneChip. For GLUT9, marker rs10516195 located in intron 3 near to and in LD with our SNPs (7.6 kb upstream from rs6449213) showed high significance with gout (p  =  3.7*10-8).
###end p 84
###begin p 85
###xml 313 317 313 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Wallace2">[39]</xref>
###xml 374 375 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 394 395 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 506 511 506 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
In our study, we found stronger significance between genotyped markers and gout in males than in females. However, odds ratios have the same order of magnitude with a risk reduction of about 40%. It is known that serum UA levels and incidence of gout are higher in males, but tend to equalize with increasing age [39]. In our study, the relatively small female sample size (n  =  186 cases and n  =  186 controls, respectively) limits the conclusion of gender-specific effects mediated by polymorphisms in GLUT9 gene on gout.
###end p 85
###begin p 86
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 243 247 243 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WDR1</italic>
###xml 253 257 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Frazer1">[24]</xref>
###xml 259 265 259 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001948-g001">Fig. 1</xref>
###xml 543 548 543 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 588 592 588 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Li1">[18]</xref>
###xml 619 624 619 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 995 999 995 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Knight1">[40]</xref>
###xml 1100 1104 1100 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Mattick1">[41]</xref>
###xml 1137 1142 1137 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 1321 1325 1321 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Phay1">[20]</xref>
###xml 1327 1331 1327 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001948-Augustin1">[42]</xref>
###xml 1649 1654 1649 1654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 1806 1811 1806 1811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
Also, SNP rs12510549, located 235 kb upstream to GLUT9 showed significant association with gout in our study. HapMap data describe a large LD block covering two-thirds of GLUT9 and a large proportion of upstream intergenic sequence, including WDR1 gene [24] (Fig. 1). It cannot be excluded that the gene encoding WDR1, also known as actin interacting protein 1 (AIP1) contributed at least to a minor portion to the association signals for serum UA levels and gout. Thus far, no functional variants, explaining the effect on serum UA levels in GLUT9 gene, could be identified by Li et al. [18]. The four SNPs within the GLUT9 gene region analysed in our study were located in intronic and intergenic regions. A possible effect of a functional variant beyond changes in amino-acid composition of translated protein could lead to altered gene expression, which can be modulated by the concerted action of multiple transcription factors over long distances and, thus, be influenced by multiple SNPs [40]. It could be shown that gene regulatory elements are harboured in non-coding and intergenic regions [41]. The biological function of the GLUT9 gene is not fully understood yet. It is known, however, that GLUT9 plays an important role as transmembrane sugar transporter and is highly expressed in liver and kidney tubules [20], [42]. Therefore, altered function or expression of GLUT9 in liver may interfere with UA metabolism and increase production of UA, whereas an effect in kidney could lead to reduced renal UA excretion. With elevated serum UA levels, the risk for gout increases considerably, which can be seen in the association analysis of GLUT9 gene polymorphisms with the phenotype "gout". However, without the knowledge of serum UA levels in our study, we cannot exclude more direct effects of GLUT9 gene variants on gout.
###end p 86
###begin p 87
###xml 206 211 206 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 334 339 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 391 396 391 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 538 543 538 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
###xml 752 759 752 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t001">Table 1</xref>
###xml 819 826 819 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001948-t002">Table 2</xref>
###xml 1456 1464 <span type="species:ncbi:9606">patients</span>
###xml 1618 1625 <span type="species:ncbi:9606">patient</span>
In the second case-control analysis, the hypothesis of a causal link of hyperuricemia and elevated risk for CAD or MI was addressed. In a large case-control study, we found no association of the markers in GLUT9 with CAD/MI. In addition, GWA studies on CAD/MI revealed no significant association signal of SNP markers in the extended GLUT9 region. Hence, it is unlikely for polymorphisms in GLUT9 to be major contributors to the risk for CAD or MI. Moreover, a pathophysiologic link between gout and CAD via genetic variations within the GLUT9 gene appears doubtful. No difference in the prevalence of CAD/MI in the gout case-control sample was observed: 67.5% and 65.9% of the gout cases and gout-free controls, respectively, were affected by CAD/MI (Table 1). However, the reverse was not true for the CAD/MI sample (Table 2). Here, the prevalence of gout and of all components of the metabolic syndrome studied was significantly higher in CAD/MI cases than in CAD/MI-free controls. Due to the study design, we did not dispose of prevalence data for gout until the time point of inclusion and not at the time of the first CAD/MI event. Therefore, prospective analyses on the role of gout on the development of CAD cannot be derived from our data and only descriptive evidence for the relationship between gout and CAD can be given. In addition, it has to be mentioned that our sample provides a special subgroup of the general population and even of CAD patients. This is caused by the inclusion criteria of the German MI Family Study, where particularly high risk individuals from MI families were recruited (index patient suffering from MI before the age of 60 years and further siblings with severe manifestation of CAD/MI agreeing to participate in the study).
###end p 87
###begin p 88
###xml 109 117 <span type="species:ncbi:9606">patients</span>
Several limitations of our study have to be considered. The gout phenotype was assessed retrospectively from patients records and medical history without knowledge of serum UA levels. However, we combined two levels of evidence, namely medical history readings at time of inclusion and at two-years and five-years follow-up interview together with self-reported history of gout. We only included control individuals without history of gout and without intake of uricostatics or uricosuric agents. The two most confounding effects on association with gout - age and gender - were excluded by carefully matching these parameters between gout cases and gout-free controls. However, in the CAD/MI sample an imbalance on gender existed due to the selection approach of the control individuals in our German MI Family Study (relatives of cases for a disease having a much higher prevalence in males). Therefore, we adjusted for male gender and other cardiovascular risk factors with no increase in significance. Additionally, the two analyzed GWA studies on CAD/MI included a more balanced gender distribution between cases and controls (e. g. in the Cardiogenics MI sample 591 male cases and 284 female cases, respectively, were compared with 813 male controls and 831 female controls, respectively). Here, separate analysis of the four SNPs (rs6855911, rs7442295, rs6449213, and rs12510549) revealed no association with MI, even after adjustment for male gender.
###end p 88
###begin p 89
###xml 76 81 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
In conclusion, our study demonstrates strong evidence that polymorphisms in GLUT9 gene are associated with increased susceptibility to gout. Furthermore, these SNPs are unlikely to play a causal role in the pathogenesis of CAD or MI. Additional functional analyses are warranted to further elucidate the role of GLUT9 in the pathophysiology of hyperuricemia and gout.
###end p 89
###begin title 90
Online Resources
###end title 90
###begin p 91
Cardiogenics data:
###end p 91
###begin p 92
WTCCC data:
###end p 92
###begin p 93
Framingham SHARe:  phs000007.v2.p1
###end p 93
###begin p 94
PLINK: approximatelypurcell/plink/
###end p 94
###begin p 95
HaploView:
###end p 95
###begin p 96
G*Power:
###end p 96
###begin p 97
HapMap:
###end p 97
###begin p 98
###xml 45 57 <span type="species:ncbi:9606">participants</span>
We appreciate the invaluable contribution of participants of the German MI Family Study. We gratefully acknowledge the excellent technical assistance of Josef Simon and Michaela Vostner.
###end p 98
###begin title 99
References
###end title 99
###begin article-title 100
Epidemiology of hyperuricemia and gout.
###end article-title 100
###begin article-title 101
Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.
###end article-title 101
###begin article-title 102
Pathogenesis of gout.
###end article-title 102
###begin article-title 103
Gout, diet, and the insulin resistance syndrome.
###end article-title 103
###begin article-title 104
Gout.
###end article-title 104
###begin article-title 105
Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study.
###end article-title 105
###begin article-title 106
Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey.
###end article-title 106
###begin article-title 107
###xml 91 94 <span type="species:ncbi:9606">men</span>
Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study.
###end article-title 107
###begin article-title 108
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.
###end article-title 108
###begin article-title 109
A common variant on chromosome 9p21 affects the risk of myocardial infarction.
###end article-title 109
###begin article-title 110
A common allele on chromosome 9 associated with coronary heart disease.
###end article-title 110
###begin article-title 111
Genomewide association analysis of coronary artery disease.
###end article-title 111
###begin article-title 112
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.
###end article-title 112
###begin article-title 113
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants.
###end article-title 113
###begin article-title 114
A genome-wide association study identifies novel risk loci for type 2 diabetes.
###end article-title 114
###begin article-title 115
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes.
###end article-title 115
###begin article-title 116
Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes.
###end article-title 116
###begin article-title 117
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLUT9</italic>
The GLUT9 Gene Is Associated with Serum Uric Acid Levels in Sardinia and Chianti Cohorts.
###end article-title 117
###begin article-title 118
Genome-wide Association Study Identifies Genes for Biomarkers of Cardiovascular Disease: Serum Urate and Dyslipidemia.
###end article-title 118
###begin article-title 119
Cloning and expression analysis of a novel member of the facilitative glucose transporter family, SLC2A9 (GLUT9).
###end article-title 119
###begin article-title 120
A comprehensive linkage analysis for myocardial infarction and its related risk factors.
###end article-title 120
###begin article-title 121
Lymphotoxin-alpha and galectin-2 SNPs are not associated with myocardial infarction in two different German populations.
###end article-title 121
###begin article-title 122
Assessment of blood pressure measurement quality in the baseline surveys of the WHO MONICA project.
###end article-title 122
###begin article-title 123
###xml 20 25 <span type="species:ncbi:9606">human</span>
A second generation human haplotype map of over 3.1 million SNPs.
###end article-title 123
###begin article-title 124
PLINK: a tool set for whole-genome association and population-based linkage analyses.
###end article-title 124
###begin article-title 125
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 125
###begin article-title 126
G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences.
###end article-title 126
###begin article-title 127
Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.
###end article-title 127
###begin article-title 128
Gout: epidemiology and lifestyle choices.
###end article-title 128
###begin article-title 129
A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy.
###end article-title 129
###begin article-title 130
Independent impact of gout on mortality and risk for coronary heart disease.
###end article-title 130
###begin article-title 131
Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country.
###end article-title 131
###begin article-title 132
High serum uric acid as a novel risk factor for type 2 diabetes mellitus.
###end article-title 132
###begin article-title 133
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
###end article-title 133
###begin article-title 134
Genetics and heritability of coronary artery disease and myocardial infarction.
###end article-title 134
###begin article-title 135
Diagnosis and management of gout.
###end article-title 135
###begin article-title 136
Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: hint for genotyping error?
###end article-title 136
###begin article-title 137
The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports.
###end article-title 137
###begin article-title 138
Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population.
###end article-title 138
###begin article-title 139
Functional implications of genetic variation in non-coding DNA for disease susceptibility and gene regulation.
###end article-title 139
###begin article-title 140
RNA regulation: a new genetics?
###end article-title 140
###begin article-title 141
###xml 39 44 <span type="species:ncbi:9606">human</span>
Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking.
###end article-title 141
###begin p 142
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 142
###begin p 143
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by grants from the National Genome Network (NGFN, 01GS0417), Deutsche Forschungsgemeinschaft (He1921/9-1), the Vaillant-Stiftung (C.H., H.S.), the Deutsche Stiftung fuer Herzforschung, and the EU sponsored project Cardiogenics (LSH-2005-037593).
###end p 143

